Exchange: NASDAQ·Updated 11:09 AM EDT
News
all
press releases
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -50.00% and -11.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates
Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +14.29% and +1.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of +114.29% and +18.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
New Strong Sell Stocks for July 15th
BV, RAIL and HRTX have been added to the Zacks Rank #5 (Strong Sell) List on July 15th, 2026.
Zacks
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?
The selloff highlighted the risks facing smaller companies operating in biotechnology and emerging technology.
Stocktwits
Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?
Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright...
Yahoo! Finance: News
Heron Therapeutics Q1 Earnings Call Highlights
Heron Therapeutics Q1 Earnings Call Highlights...
Yahoo! Finance: News
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -33.33% and -3.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of +242.86% and +44.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.